Researchers have recently determined that the medication, originally developed to treat diabetes, can contribute to weight loss and reduce a patient's MACE risk by up to 20%. 

One expert believes the lack of standardization for how diagnostic imaging in conducted and reported has led to a major underdiagnosis of HCM.

Weekly subcutaneous treatments of semaglutide, originally developed to treat diabetes, are sold and marketed under the brand name Wegovy.

Matthew Martinez, MD, detailed the many ways HCM care management is changing during an exclusive interview at ASE 2023.

COVID-19 opened the eyes of many cardiology researchers that infections may promote inflammation in atherosclerotic plaques, leading to cardiac events.

Researchers tracked data from nearly 38,000 obese patients who underwent TAVR or SAVR, sharing their findings in a new meta-analysis. 

Should an energy drink with more caffeine than five cans of soda be marketed to kids? Sen. Chunk Schumer shared his concerns in a new letter to FDA Commissioner Robert Califf, MD, a veteran cardiologist.